Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Reindollar

Gastroenterology Salisbury, NC Medical Doctor

NPI 1851382287 CMS profile 128867

1809 Brenner Ave Ste 102, Suite 360, Salisbury, NC 28144

Open in the dashboard

General payments

$430,003

466 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,059,835 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Robert Reindollar of Salisbury, NC is reported in the CMS Open Payments database as having received $430,003 across 466 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,059,835 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $70,996 88
2024 General $53,419 37
2023 General $70,737 82
2022 General $64,291 98
2021 General $33,365 35
2020 General $50,678 42
2019 General $86,517 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Reindollar
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Robert Reindollar were reported at $70,996. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Robert Reindollar Gastroenterology median Middle half National median
2019 $86,517 $417 $126–$1,100 $163
2020 $50,678 $224 $74–$624 $114
2021 $33,365 $352 $106–$1,054 $132
2022 $64,291 $448 $129–$1,270 $149
2023 $70,737 $533 $150–$1,390 $160
2024 $53,419 $605 $160–$1,606 $164
2025 $70,996 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $169,183 176 payments
  2. Intercept Pharmaceuticals, Inc. $165,731 109 payments
  3. Gilead Sciences, Inc. $93,376 98 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $440 22 payments
  5. Madrigal Pharmaceuticals $336 9 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $198 9 payments
  7. Janssen Biotech, Inc. $190 9 payments
  8. Celgene Corporation $173 13 payments
  9. Daiichi Sankyo Inc. $87 5 payments
  10. Novo Nordisk Inc $52 2 payments
  11. Other $237 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $238,355 81 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $109,020 28 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $28,400 12 payments
  4. Travel and Lodging $21,982 56 payments
  5. Consulting Fee $15,000 4 payments
  6. Food and Beverage $11,716 277 payments
  7. Honoraria $5,530 8 payments
Products named General payments · program years 2019–2025
  1. MAVYRET $165,353 140 payments
  2. OCALIVA Hepatology / Gastroenterology $123,151 71 payments
  3. Epclusa $83,351 67 payments
  4. OCALIVA Hepatology Gastroenterology $42,580 38 payments
  5. RINVOQ $447 11 payments
  6. SKYRIZI Immunology $323 10 payments
  7. REZDIFFRA $284 7 payments
  8. XIFAXAN $242 11 payments
  9. TRULANCE $197 11 payments
  10. SKYRIZI Immunology $191 4 payments
  11. Other $1,431 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

466 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record